New chemo combo aims to shrink tough breast tumors before surgery
NCT ID NCT01525966
Summary
This study tested whether giving two chemotherapy drugs (carboplatin and nab-paclitaxel) before surgery could effectively shrink tumors in patients with a hard-to-treat type of breast cancer called triple-negative breast cancer. The goal was to see if this approach could completely eliminate cancer cells in the breast and lymph nodes by the time of surgery, which is linked to better long-term outcomes. Researchers also tracked side effects and collected tissue samples to learn more about how these cancers respond to treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
City of Hope- South Pasadena Cancer Center
South Pasadena, California, 91030, United States
Conditions
Explore the condition pages connected to this study.